BioSpace News Archive

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of current board member, Joel Lewis, to the position of Chief Executive Officer (CEO) and President.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citi’s 15th Annual BioPharma Conference,

Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc. (“VYNE Therapeutics”).

The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System®.

Seneca Biopharma, Inc., a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, provided the following letter from Dr. Ken Carter, the Company’s Executive Chairman.

BiomX XMarker biomarker discovery platform to potentially inform Boehringer Ingelheim’s development of IBD therapeutics

Specialty medical supply company SLI Medical announced the company has delivered more than 15,000 COVID-19 safety toolkits to JobsOhio to support small businesses in safely reopening during the pandemic.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in three upcoming virtual investor conferences.

With best-in-class team and targeted investment initiatives, Company optimally positioned to increase market share in highly valued hemostat market